A federal judge in Newark on Tuesday gave final approval to a $688 million settlement of litigation over the cholesterol drug Vytorin.
Class counsel called the settlement the largest ever in a securities-fraud case against a pharmaceutical company.
A federal judge in Newark gives final approval to a $688 million settlement of litigation over the cholesterol drug Vytorin.
October 03, 2013 at 03:10 AM
1 minute read
A federal judge in Newark on Tuesday gave final approval to a $688 million settlement of litigation over the cholesterol drug Vytorin.
Class counsel called the settlement the largest ever in a securities-fraud case against a pharmaceutical company.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS